Incyte Corporation manufactures Jakafi [1].
Who Else is Involved with Jakafi?
Novartis partnered with Incyte to develop and commercialize Jakafi outside the United States, excluding Europe, Switzerland, and China [2]. In Europe, Switzerland, and China, the drug is developed and commercialized by Incyte [2].
What is Jakafi Used For?
Jakafi is a Janus kinase (JAK) inhibitor indicated for the treatment of adults and certain pediatric patients with myelofibrosis [1]. It is also used for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea [1]. Additionally, Jakafi is approved for the treatment of steroid-refractory acute graft versus host disease (GVHD) in adults and children two years of age and older [1].
When Did Jakafi Become Available?
Jakafi received U.S. Food and Drug Administration (FDA) approval for myelofibrosis in November 2011 [3]. Its approval for polycythemia vera followed in December 2014 [3]. The FDA approved Jakafi for acute GVHD in June 2017 [3].
What Are the Potential Side Effects of Jakafi?
Common side effects of Jakafi can include low blood cell counts (anemia, thrombocytopenia, neutropenia), diarrhea, nausea, vomiting, and abdominal pain [1]. Serious side effects may involve increased risk of serious infections, blood clots, heart attack, stroke, and certain types of cancer [1].
What is the Mechanism of Action for Jakafi?
Jakafi works by inhibiting Janus kinases (JAKs), which are involved in signaling pathways that regulate blood cell formation and immune function [1]. By blocking these pathways, Jakafi helps to reduce the overproduction of abnormal blood cells and control inflammation associated with myelofibrosis, polycythemia vera, and GVHD [1].
What is the Patent Status for Jakafi?
Information regarding the patent status and exclusivity for Jakafi can be found on DrugPatentWatch.com [4]. DrugPatentWatch.com provides details on patent expiration dates and other relevant intellectual property information for pharmaceutical products [4].